Entrada Therapeutics, Inc. (TRDA)
| Market Cap | 191.30M -39.0% |
| Revenue (ttm) | 3.98M -93.5% |
| Net Income | -161.39M |
| EPS | -3.84 |
| Shares Out | 36.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 546,529 |
| Open | 4.94 |
| Previous Close | 4.96 |
| Day's Range | 4.81 - 5.51 |
| 52-Week Range | 4.11 - 16.45 |
| Beta | -0.15 |
| Analysts | Strong Buy |
| Price Target | 17.75 (+238.74%) |
| Earnings Date | Nov 5, 2026 |
About TRDA
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was f... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for TRDA stock is "Strong Buy." The 12-month stock price target is $17.75, which is an increase of 238.74% from the latest price.
News
Entrada Therapeutics price target lowered to $13 from $17 at Guggenheim
Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on Entrada Therapeutics (TRDA) to $13 from $17 and keeps a Buy rating on the shares. Interim Phase 1/2 data on…
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
-- ELEVATE-45-201 Cohort 2 (10 mg/kg) enrollment complete with data expected in H1 2027 -- BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an i...
Entrada Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Four clinical readouts are expected through H1 2027, including Vertex’s DM1 interim data and three DMD updates. Management highlighted functional benefit at low dystrophin, dose-response potential, and cash runway into Q4 2027.
Entrada Therapeutics price target lowered to $10 from $11 at Roth Capital
Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $10 from $11 and keeps a Buy rating on the shares. The firm states that October’s ENTR-601-45 biomarker…
Entrada Therapeutics reports Q3 EPS (94c), consensus (99c)
Reports Q3 revenue $905,000, consensus $5.87M. “The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical...
Entrada Therapeutics Reports Third Quarter 2026 Financial Results
-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 -- -- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 202...
Entrada Therapeutics Quarterly report: Q3 2026
Entrada Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Entrada Therapeutics Earnings release: Q3 2026
Entrada Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Entrada Therapeutics Slides: Corporate presentation
Entrada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
Entrada Therapeutics appoints Linea Aspesi as chief people officer
Entrada Therapeutics (TRDA) announced the appointment of Linea Aspesi as chief people officer. Prior to Entrada, Aspesi served as chief people officer at KalVista Pharmaceuticals.
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling...
Entrada Therapeutics reports data from Cohort 1 of ELEVATE-45-201 clinical study
Entrada Therapeutics (TRDA) announced topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose, or MAD, portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENT...
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLO...
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non...
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 20...
Entrada Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The EEV platform enables superior delivery and safety for oligonucleotide therapies, with clinical programs in DMD showing early functional benefits and strong safety. Upcoming data from higher-dose cohorts and expansion studies aim to confirm dose-dependent efficacy and support accelerated approval, while a robust financial position and a strategic Vertex partnership underpin future growth.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purc...
Entrada Therapeutics price target raised to $11 from $10 at Roth Capital
Roth Capital raised the firm’s price target on Entrada Therapeutics (TRDA) to $11 from $10 and keeps a Buy rating on the shares after the company reported Q2 earnings and…
Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04)
Reports Q2 revenue $898,000, consensus $2.23M. “With multiple data readouts ahead in 2026, we are well positioned to deliver on important clinical milestones and further demonstrate the potential of o...
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVA...
Entrada Therapeutics Earnings release: Q2 2026
Entrada Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Entrada Therapeutics Quarterly report: Q2 2026
Entrada Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Entrada Therapeutics Slides: Corporate presentation
Entrada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Entrada Therapeutics Transcript: AGM 2026
The meeting covered board introductions, voting on four key proposals, and confirmation of a quorum. All proposals, including director elections and plan amendments, were approved by stockholders, with no questions raised during the session.
Entrada Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Entrada's EEV platform shows strong safety and early functional benefit in DMD, with higher dystrophin levels expected in upcoming cohorts. The pipeline includes DM1 (with Vertex) and inherited retinal diseases, with robust preclinical data and a solid cash runway into 2027.